August 26, 2016 5:30pm
… As I had stated this a.m., “our” universe’s pricing was ripening for an uptick for the oversold and it jumped
Right again … as the IBB jumped +0.80%
When the volume is low a few trades can move the sector higher
Pre-open indication’s tally: 3 hit (BLUE, CLLS and XON) and 1 miss (AGTC)
I answer one question; in which company should investors put, keep and commit their money!
Do you care what happened today, you should … because it has implications to Monday's sector activity? Where has today’s market gone – subscribe and find out.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. stocks closed mixed on Friday, with utilities lagging, as investors digested remarks made by Fed Chair Janet Yellen and Vice Chair Stanley Fischer.
The NASDAQ closed UP +6.71 or +0.13% to 5,218.92 and the DOW closed DOWN -53.01 or -0.29% to 18,395.40.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was positive with an A/DL of 28/13 and 2 flats;
- The mid-day was barely positive with an A/DL of 19/20 and 4 flats;
- The closing bell was positive with A/DL of 25/17 and 1 flat;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCGT&RT) sector was positive at the opening bell, barely positive at the mid-day with the sector closing positive.
- Considering the day, of 43 covered companies – 32 were up at 10:30 am and 29 were up at 11:30 am then the sector dropped to 20 ups versus 19 downs and closed with 25 ups and 17 downs.
For what was going on Friday – traders got nervous as a week ended and the weekend progressed, the pendulum always swings too far too often!
History lesson:
- The three major indexes were on track to post weekly losses, with the NASDAQ on the verge of snapping an eight-week winning streak.
- Stocks, however, have held in a narrow range, as the S&P hasn't closed 1% higher or lower for 34 straight sessions.
I’m still holding on to “some” equities, recommending BUYING the oversold while sticking my head in the sand until after Labor Day!
Call me cantankerous, contrarian or even a curmudgeon but at the least I get it right and investors make money!
Today’s Bottom Line:
As an investor, you can control lots of risks by proxy voting and speaking-up to managements – it’s TIME to be VOCAL!
Pre-open indication’s tally: 3 hit and 1 miss:
- Applied Genetic Technologies (AGTC) closed DOWN -$0.08 – miss;
- bluebird bio (BLUE) closed UP +$1.26 – hit;
- Cellectis SA (CLLS) closed UP +$0.10 – hit;
- Intrexon (XON) closed UP +$0.44 – hit;
Review my fear gauge or the CBOE Volatility Index (VIX):
- Friday traded near 13.65;
- Thursday traded near 14;
- Wednesday traded 13.39;
- Tuesday traded 12.19;
- Monday traded 12.6;
- Last Friday traded near 11.6;
Decliners:
- VistaGen (VTGN) -7.81% after Thursday’s+1.25%;
- Vericel (VCEL -6.64% after Thursday’s -4.74%
- Northwest Bio (NWBO) -3.01%;
- Aduro Biotech (ADRO) -2.76% after Thursday’s -5.43%;
- Fibrocell (FCSC) -2.24%
Advancers:
- ReNeuron (RENE.L ) -4.55%;
- StemCells (STEM) +4.49%;
- uniQure (QURE) +3.28%;
- Opexa (OPXA) +3.49% after Thursday’s -4.87%;
- Adverum (ADVM) +2.99% after Thursday’s -9.14%;
Flat:
- International Stem Cell (ISCO) at $1.95
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
